bioAffinity Technologies, Inc. has received notification from the China National Intellectual Property Administration regarding the allowance of a patent application related to its noninvasive lung cancer diagnostic methods. This development is significant given China's substantial population of smokers, which contributes to the country's high rate of lung cancer. The patent, titled "System and Method for Determining Lung Health," involves the use of specific antibodies and the porphyrin TCPP to label cell populations in sputum, utilizing flow cytometry to detect lung cancer cells. This notification is part of bioAffinity's strategy to expand its proprietary diagnostic platform internationally.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.